Merck Hikes Revenue Outlook as New Drug Sales Grow, but Cuts Profit Guidance Due to Deal Charges Merck's latest earnings report has sent a mixed signal to investors and industry watchers alike.
The pharmaceutical giant's revenue outlook has been boosted by strong sales of its newer products, while the company's profit guidance has taken a hit due to charges tied to its acquisition spree.
The growth in sales of new products such as Keytruda and Winrevair is significant, with revenue from these medications up 5% and 75%, respectively, compared to the same period last year.